Physician profile
David Chung
NPI 1417914557
$2,330.29
in general payments reported to CMS, 2019-2025
27 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $218 · 2021: $118 · 2022: $589 · 2023: $64.51 · 2024: $208 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426 · Travel and Lodging: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.25 |
| Travel and Lodging | $322.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $355.95 | 2022-2024 | Gore Enform Preperitoneal Biomaterial |
| Davol INC. | $353.22 | 2024-2025 | Phasix Mesh |
| Lilly USA, LLC | $240.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $135.30 | 2019-2022 | |
| Abbvie INC. | $131.15 | 2019-2024 | Dalvance |
| Stryker Corporation | $107.87 | 2025 | 1788, Spy-Phi System |
| Novo Nordisk INC | $99.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.81 | 2019-2022 | |
| Amgen INC. | $86.94 | 2019-2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $83.51 | 2019-2022 | |
| Glaxosmithkline, LLC. | $73.84 | 2019-2025 | Shingrix, Pediarix, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.76 | 2019-2022 | |
| Amarin Pharma, INC. | $66.93 | 2019-2020 | |
| Allergan, INC. | $64.33 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $57.30 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.63 | 2019-2022 | |
| Pfizer INC. | $47.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $45.62 | 2019-2022 | |
| Astellas Pharma US INC | $42.00 | 2019 | |
| Biosense Webster, INC. | $27.25 | 2023 | Carto 3 |
| Dexcom, INC. | $19.55 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.20 | 2025 | |
| Sunovion Pharmaceuticals INC. | $13.90 | 2022 | |
| Mylan Specialty L.P. | $13.73 | 2019 | |
| Sumitomo Pharma America, INC. | $13.46 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.78 | 2022 | |
| Sanofi Pasteur INC. | $12.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.